ABVC BioPharma, Inc. (ABVC)
US Market

ABVC BioPharma, Inc. (ABVC) Stock Price & Analysis


ABVC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.50 - $3.13
Previous Close$0.6
Average Volume (3M)869.66K
Market Cap
Enterprise Value$21.39M
Total Cash (Recent Filing)$1.40M
Total Debt (Recent Filing)$3.11M
Price to Earnings (P/E)-1.5
Mar 30, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding32,632,329
10 Day Avg. Volume26,008
30 Day Avg. Volume869,664
Standard Deviation0.20
Financial Highlights & Ratios
Price to Book (P/B)3.36
Price to Sales (P/S)51.42
Price to Cash Flow (P/CF)3472528.50
P/FCF Ratio-2.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue62.37
Enterprise Value/Gross Profit61.00
Enterprise Value/Ebitda-1.21
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was ABVC BioPharma, Inc.’s price range in the past 12 months?
ABVC BioPharma, Inc. lowest stock price was $0.50 and its highest was $3.13 in the past 12 months.
    What is ABVC BioPharma, Inc.’s market cap?
    Currently, no data Available
    When is ABVC BioPharma, Inc.’s upcoming earnings report date?
    ABVC BioPharma, Inc.’s upcoming earnings report date is Mar 30, 2023 which is tomorrow.
      How were ABVC BioPharma, Inc.’s earnings last quarter?
      ABVC BioPharma, Inc. released its earnings results on Nov 14, 2022. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.09.
        Is ABVC BioPharma, Inc. overvalued?
        According to Wall Street analysts ABVC BioPharma, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does ABVC BioPharma, Inc. pay dividends?
          ABVC BioPharma, Inc. does not currently pay dividends.
          What is ABVC BioPharma, Inc.’s EPS estimate?
          ABVC BioPharma, Inc.’s EPS estimate is -$0.15.
            How many shares outstanding does ABVC BioPharma, Inc. have?
            ABVC BioPharma, Inc. has 32,632,328 shares outstanding.
              What happened to ABVC BioPharma, Inc.’s price movement after its last earnings report?
              ABVC BioPharma, Inc. reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -4%.
                Which hedge fund is a major shareholder of ABVC BioPharma, Inc.?
                Currently, no hedge funds are holding shares in ABVC


                ABVC BioPharma, Inc. Stock Smart Score

                Not Ranked


                20 days / 200 days


                Return on Equity
                Trailing 12-Months
                Asset Growth
                Trailing 12-Months
                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                ABVC BioPharma, Inc.

                American BriVision (Holding) Corp. is a clinical stage biopharmaceutical company, which focuses on the development of new drugs and medical devices. The company also integrates research achievements from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. It conducts clinical trials of translational medicine for Proof of Concept and out-licenses it to international pharmaceutical companies. Its products include BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia. The company was founded in 1990 and is headquartered in Fremont, CA.


                Top 5 ETFs holding ABVC

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold ABVC. The ETFs are listed according to market value of ABVC within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Spruce Biosciences
                Codiak BioSciences
                Inhibitor Therapeutics
                Marker Therapeutics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis